User menu

What is the link between HLA-G polymorphisms and post-transplantation lipid disorders?

Bibliographic reference Kuypers, Dirk R. J.. What is the link between HLA-G polymorphisms and post-transplantation lipid disorders?. In: Pharmacogenomics, Vol. 11, no. 1, p. 12-12 (2010)
Permanent URL http://hdl.handle.net/2078.1/34834
  1. Palikhe A., Sinisalo J., Seppänen M., Valtonen V., Nieminen M. S., Lokki M. L., Human MHC region harbors both susceptibility and protective haplotypes for coronary artery disease, 10.1111/j.1399-0039.2006.00735.x
  2. Naji Abderrahim, Durrbach Antoine, Carosella Edgardo D., Rouas-Freiss Nathalie, Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways, 10.1016/j.humimm.2006.10.017
  3. Bahri R., Hirsch F., Josse A., Rouas-Freiss N., Bidere N., Vasquez A., Carosella E. D., Charpentier B., Durrbach A., Soluble HLA-G Inhibits Cell Cycle Progression in Human Alloreactive T Lymphocytes, 10.4049/jimmunol.176.3.1331
  4. Piancatelli D., Maccarone D., Liberatore G., Parzanese I., Clemente K., Azzarone R., Pisani F., Famulari A., Papola F., HLA-G 14-bp Insertion/Deletion Polymorphism in Kidney Transplant Patients With Metabolic Complications, 10.1016/j.transproceed.2009.03.028
  5. KUYPERS D, NAESENS M, VERMEIRE S, VANRENTERGHEM Y, The impact of uridine diphosphate–glucuronosyltransferase 1A9 () gene promoter region single-nucleotide polymorphisms and on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients, 10.1016/j.clpt.2005.06.007
  6. van Schaik R H N, van Agteren M, de Fijter J W, Hartmann A, Schmidt J, Budde K, Kuypers D, Le Meur Y, van der Werf M, Mamelok R, van Gelder T, UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients, 10.1038/clpt.2009.83
  7. Gaston R. S., Kaplan B., Shah T., Cibrik D., Shaw L. M., Angelis M., Mulgaonkar S., Meier-Kriesche H.-U., Patel D., Bloom R. D., Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial, 10.1111/j.1600-6143.2009.02668.x
  8. van Gelder Teun, Silva Helio Tedesco, de Fijter Johan W., Budde Klemens, Kuypers Dirk, Tyden Gunnar, Lohmus Aleksander, Sommerer Claudia, Hartmann Anders, Le Meur Yann, Oellerich Michael, Holt David W., Tönshoff Burkhard, Keown Paul, Campbell Scott, Mamelok Richard D., Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial : , 10.1097/tp.0b013e318186f98a
  9. Le Meur Y., Büchler M., Thierry A., Caillard S., Villemain F., Lavaud S., Etienne I., Westeel P.-F., de Ligny B. H., Rostaing L., Thervet E., Szelag J. C., Rérolle J.-P., Rousseau A., Touchard G., Marquet P., Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, 10.1111/j.1600-6143.2007.01983.x
  10. Leonard M. O., Kieran N. E., Howell K., Burne M. J., Varadarajan R., Dhakshinamoorthy S., Porter A. G., O'Farrelly C., Rabb H., Taylor C. T., Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury, 10.1096/fj.06-5097fje
  11. Aguilera I., Alvarez-Marquez A., Gentil M. A., Fernandez-Alonso J., Fijo J., Saez C., Wichmann I., Nunez-Roldan A., Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients, 10.1093/ndt/gfm955
  12. Yang, Int. J. Mol. Med., 14, 855 (2004)
  13. Branten Amanda J.W., Mulder Theo P.J., Peters WilbertH.M., Assmann Karel J.M., Wetzels Jack F.M., Urinary Excretion of Glutathione S Transferases Alpha and Pi in Patients with Proteinuria: Reflection of the Site of Tubular Injury, 10.1159/000045644
  14. Singh Ranjana, Manchanda Parmeet K., Kesarwani Pravin, Srivastava Aneesh, Mittal Rama D., Influence of genetic polymorphisms inGSTM1,GSTM3,GSTT1andGSTP1on allograft outcome in renal transplant recipients, 10.1111/j.1399-0012.2009.00985.x
  15. Bastani Sam, Sherman William, Schnickel Gabriel T., Hsieh George R., Bhatia Rubina, Fishbein Michael C., Ardehali Abbas, Chemokine Receptor Blockade With a Synthetic Nonpeptide Compound Attenuates Cardiac Allograft Vasculopathy : , 10.1097/tp.0b013e3181b9ccd5
  16. Mengel M., Tubular Chimerism Occurs Regularly in Renal Allografts and Is Not Correlated to Outcome, 10.1097/01.asn.0000120369.92378.54
  17. Rüster M., Sperschneider H., Fünfstück R., Stein G., Gröne H.-J., Differential expression of b-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts, 10.5414/cnp61030
  18. Prasad Pushplata, Tiwari Arun K, Kumar KM Prasanna, Ammini AC, Gupta Arvind, Gupta Rajeev, Thelma BK, Association of TGFβ1, TNFα, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians, 10.1186/1471-2350-8-20
  19. Cha Ran-hui, Yang Seung Hee, Kim Hyo Sang, Kim Sun Moon, Park Myoung Hee, Ha Jongwon, Kim Yon Su, Genetic interactions between the donor and the recipient for susceptibility to acute rejection in kidney transplantation: polymorphisms of CCR5, 10.1093/ndt/gfp317